<DOC>
	<DOCNO>NCT01083992</DOCNO>
	<brief_summary>Sedentary lifestyle poor dietary choice lead weight gain epidemic increase risk develop nonalcoholic fatty liver disease ( NAFLD ) . The strong relationship insulin resistance NAFLD suggest add Vitamin D TO insulin sensitize therapy Galvus ( vitagliptin ) might beneficial prevention improvement NAFLD . Considering close relationship NAFLD T2DM lipid metabolism , assume add vitamin D Galvus , may effective NAFLD improve lipid metabolism improve type 2 diabetes mellitus ( T2DM ) .</brief_summary>
	<brief_title>Role Vitagliptin Vitamin D Treatment Non Alcoholic Fatty Liver Disease ( NAFLD )</brief_title>
	<detailed_description>Sedentary lifestyle poor dietary choice lead weight gain epidemic increase risk develop nonalcoholic fatty liver disease ( NAFLD ) . The strong relationship insulin resistance NAFLD suggest add vitamin D insulin sensitize therapy Galvus ( vitagliptin ) might beneficial prevention improvement NAFLD . Considering close relationship NAFLD T2DM lipid metabolism , assume add vitamin D Galvus may effective NAFLD improve lipid metabolism improve T2DM . Methods : 60 patient NAFLD ( Diagnosed Ultrasound , increase ALT level hepatomegaly ) enrol , divide 2 arm Galvus plus Vitamin D vs. Galvus alone . Biochemistry , hepatic triglyceride , histology , RNA gene expression collagen , MTP , SREP-1 , PPAR-alpha , LDLR measure . 2 separate liver biopsy perform screen 6 month baseline . Expected result : Long-term combination therapy vitagliptin Vitamin D significantly reduce steatosis , inflammation fibrosis liver compare long-term monotherapy . We expect also combination therapy also significantly increase expression microsomal triglyceride transfer protein ( MTP ) peroxisome proliferators-activated receptor-α1 ( PPAR-α1 ) liver , compare monotherapy , may lead improvement lipid metabolic disorder . Conclusion : Combination therapy vitagliptin vitamin D , 24 week improve histopathology finding NAFLD .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>1865 year old Men woman NAFLD per US Increased ALT level Hepatomegaly Liver biopsy within 2 year Other liver disease ( HBV , HCV ) Hepatocellular carcinoma Decompensated liver disease Use steroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>NAFLD</keyword>
	<keyword>Galvus</keyword>
	<keyword>vitamin D</keyword>
</DOC>